Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The ...

Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...

RIT’s biology BS prepares you for careers in research, biotech, conservation, and health fields through hands-on lab and field work. Undergraduate Research: Collaborate with research mentors starting ...

The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China Background: This study systematically compares clinical trial patterns of ...

The Department of Biology at Saint Louis University explores the dynamic science with the aim of gaining a better understanding of the processes of living organisms. Biologists search for answers to ...

Novartis has agreed to license and develop Arrowhead Pharmaceuticals’ preclinical stage small interfering RNA (siRNA) therapy ARO-SNCA, a potential treatment for Parkinson’s disease and other ...

The human biology major will provide students with a broad biological understanding of our species, from molecules, genes, and cells to tissues, organ systems and organism/environment interactions.

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...

The ADARx Pharmaceuticals partnership, which could be worth “several billion dollars” in the end, adds to AbbVie’s existing work in the space after the $1.4 billion acquisition of Aliada Therapeutics ...

Chronic hepatitis B (CHB) remains a significant global health burden, with existing therapies including nucleos(t)ide analogs, interferon, siRNA, and therapeutic vaccines demonstrating limited success ...